Citadel Advisors’s Apollo Endosurgery, Inc. APEN Stock Holding History

Citadel Advisors’s Portfolio APEN Stock Details APEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,600	Closed	-$15.9K	–	15763
2023 Q1	$15.9K	Sell	1,600 -5,800	-78%	-$57.5K	﹤0.01%	13236
2022 Q4	$73.8K	Sell	7,400 -13,400	-64%	-$99.9K	﹤0.01%	11640
2022 Q3	$115K	Sell	20,800 -10,700	-34%	-$59.3K	﹤0.01%	10970
2022 Q2	$115K	Sell	31,500 -2,800	-8%	-$13.2K	﹤0.01%	11276
2022 Q1	$208K	Sell	34,300 -2,600	-7%	-$15.8K	﹤0.01%	11451
2021 Q4	$311K	Buy	36,900 +10,500	+40%	+$91.7K	﹤0.01%	10848
2021 Q3	$239K	Sell	26,400 -5,500	-17%	-$47.3K	﹤0.01%	11580
2021 Q2	$258K	Buy	+31,900	New	+$219K	﹤0.01%	11632

Citadel Advisors's APEN Position: Q2 2023 in Review

Citadel Advisors sold out of Apollo Endosurgery, Inc. (APEN) in Q2 2023, closing a stake of 13,615 shares — an estimated $135K sold.

Citadel Advisors first reported a position in APEN in Q3 2015 and held it in 13 quarters. The position peaked at $619K in Q4 2021. 0 funds tracked by Wall St. Rank hold APEN as of Q2 2023.

Citadel Advisors reported no remaining Apollo Endosurgery, Inc. position as of Q2 2023 after selling out during the quarter.
Citadel Advisors sold 13,615 Apollo Endosurgery, Inc. shares in Q2 2023, an estimated $135K.
Citadel Advisors first reported a position in Apollo Endosurgery, Inc. in Q3 2015 and held it in 13 quarters.
Citadel Advisors's Apollo Endosurgery, Inc. position peaked at $619K in Q4 2021.
0 funds tracked by Wall St. Rank held Apollo Endosurgery, Inc. as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.